First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued : TRAXV

TRAXV

Stock Data

$22.51

$0.00 (0.00%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The company is headquartered in San Diego, California.

All TRAXV Articles

1 Article

No articles found for TRAXV.

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued : TRAXV

TRAXV

$22.51

All TRAXV Articles

SpaceX IPO Could Create More Wealth Than All IPOs in the Last 20 Years Combined. Here’s Why Early Investors Are Banking On It

The No. 1 Reason to Buy and Hold Walmart Forever Has Virtually Nothing to Do With Its Brick-and-Mortar Stores

Social Security’s $68 Billion Giveaway Just Ran into a Brick Wall

Half of Thirtysomethings Prioritize Retirement Planning, but Only 29% Have an Actual Written Plan

How Closed-End Funds at a 12% Discount Can Turn $300,000 Into $30,000 a Year

SpaceX IPO Could Create More Wealth Than All IPOs in the Last 20 Years Combined. Here’s Why Early Investors Are Banking On It

The No. 1 Reason to Buy and Hold Walmart Forever Has Virtually Nothing to Do With Its Brick-and-Mortar Stores

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued : TRAXV

TRAXV

$22.51

All TRAXV Articles

SpaceX IPO Could Create More Wealth Than All IPOs in the Last 20 Years Combined. Here’s Why Early Investors Are Banking On It

The No. 1 Reason to Buy and Hold Walmart Forever Has Virtually Nothing to Do With Its Brick-and-Mortar Stores

Social Security’s $68 Billion Giveaway Just Ran into a Brick Wall

Featured Reads

Half of Thirtysomethings Prioritize Retirement Planning, but Only 29% Have an Actual Written Plan

How Closed-End Funds at a 12% Discount Can Turn $300,000 Into $30,000 a Year